A Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2018
At a glance
- Drugs Paclitaxel (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms OPERA
- Sponsors Daehwa Pharmaceutical
- 10 Aug 2018 Planned End Date changed from 1 Jan 2019 to 1 Sep 2019.
- 10 Aug 2018 Planned primary completion date changed from 1 Sep 2018 to 1 May 2019.
- 10 Aug 2018 Status changed from not yet recruiting to recruiting.